Potential Efficacy of Proteasome Inhibitor, Delanzomib, for the Treatment of Renal FibrosisAyano Sawa-Aihara(Tokushima University), Tatsuhiro Ishida(Institute of Biomedical Science)Biological and Pharmaceutical BulletinJanuary 31, 202310.1248/bpb.b22-00713Cited by 3SaveCiteExport RISWatch citationsRelated PapersIncreasing Tumor Extracellular pH by an Oral Alkalinizing Agent Improves Antitumor Responses of Anti-PD-1 Antibody: Implication of Relationships between Serum Bicarbonate Concentrations, Urinary pH, and Therapeutic Outcomes|Biological and Pharmaceutical Bulletin|2021|17